Physician profile
Warren E Milteer
NPI 1023160983
$1,226.11
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $309 · 2021: $230 · 2022: $59.32.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $273.25 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $232.92 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $142.46 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $137.10 | 2020 | |
| Neurocrine Biosciences, INC. | $109.69 | 2019-2021 | |
| Greenwich Biosciences, INC. | $102.69 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $98.71 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $66.30 | 2019 | |
| Janssen Pharmaceuticals, INC | $31.93 | 2019 | |
| Livanova USA, INC. | $20.18 | 2020 | |
| Emergent Biosolutions INC. | $10.88 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Milteer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.